TY - JOUR
T1 - High-Throughput UHPLC-MS to Screen Metabolites in Feces for Gut Metabolic Health
AU - Zawadzki, Andressa de
AU - Thiele, Maja
AU - Suvitaival, Tommi
AU - Wretlind, Asger
AU - Kim, Min
AU - Ali, Mina
AU - Bjerre, Annette F
AU - Stahr, Karin
AU - Mattila, Ismo
AU - Hansen, Torben
AU - Krag, Aleksander Ahm
AU - Legido-Quigley, Cristina
PY - 2022/2/25
Y1 - 2022/2/25
N2 - Feces are the product of our diets and have been linked to diseases of the gut, including Chron's disease and metabolic diseases such as diabetes. For screening metabolites in heterogeneous samples such as feces, it is necessary to use fast and reproducible analytical methods that maximize metabolite detection. As sample preparation is crucial to obtain high quality data in MS-based clinical metabolomics, we developed a novel, efficient and robust method for preparing fecal samples for analysis with a focus in reducing aliquoting and detecting both polar and non-polar metabolites. Fecal samples (n = 475) from patients with alcohol-related liver disease and healthy controls were prepared according to the proposed method and analyzed in an UHPLC-QQQ targeted platform in order to obtain a quantitative profile of compounds that impact liver-gut axis metabolism. MS analyses of the prepared fecal samples have shown reproducibility and coverage of n = 28 metabolites, mostly comprising bile acids and amino acids. We report metabolite-wise relative standard deviation (RSD) in quality control samples, inter-day repeatability, LOD (limit of detection), LOQ (limit of quantification), range of linearity and method recovery. The average concentrations for 135 healthy participants are reported here for clinical applications. Our high-throughput method provides a novel tool for investigating gut-liver axis metabolism in liver-related diseases using a noninvasive collected sample.
AB - Feces are the product of our diets and have been linked to diseases of the gut, including Chron's disease and metabolic diseases such as diabetes. For screening metabolites in heterogeneous samples such as feces, it is necessary to use fast and reproducible analytical methods that maximize metabolite detection. As sample preparation is crucial to obtain high quality data in MS-based clinical metabolomics, we developed a novel, efficient and robust method for preparing fecal samples for analysis with a focus in reducing aliquoting and detecting both polar and non-polar metabolites. Fecal samples (n = 475) from patients with alcohol-related liver disease and healthy controls were prepared according to the proposed method and analyzed in an UHPLC-QQQ targeted platform in order to obtain a quantitative profile of compounds that impact liver-gut axis metabolism. MS analyses of the prepared fecal samples have shown reproducibility and coverage of n = 28 metabolites, mostly comprising bile acids and amino acids. We report metabolite-wise relative standard deviation (RSD) in quality control samples, inter-day repeatability, LOD (limit of detection), LOQ (limit of quantification), range of linearity and method recovery. The average concentrations for 135 healthy participants are reported here for clinical applications. Our high-throughput method provides a novel tool for investigating gut-liver axis metabolism in liver-related diseases using a noninvasive collected sample.
KW - Bile acids
KW - Fecal metabolomics
KW - Gut-liver axis
KW - Sample preparation
KW - Targeted metabolomics
UR - http://www.scopus.com/inward/record.url?scp=85128521896&partnerID=8YFLogxK
U2 - 10.3390/metabo12030211
DO - 10.3390/metabo12030211
M3 - Journal article
C2 - 35323654
VL - 12
JO - Metabolites
JF - Metabolites
SN - 2218-1989
IS - 3
M1 - 211
ER -